Ian Smith
Impact in
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Bone health and treatments
Papers in
- Oncology 63
- HER2/EGFR in Cancer Research 35
- Cancer Treatment and Pharmacology 16
-
- Breast Cancer Treatment Studies 37
- Co-authors
- Mitch Dowsett (23 shared papers)Toby J Lasserson (3 shared papers)Aron Goldhirsch (11 shared papers)Richard D. Gelber (11 shared papers)Dariusz Woźniak (4 shared papers)Felix FitzRoy (10 shared papers)Alan Stuart Coates (9 shared papers)Beat J. K. Thurlimann (9 shared papers)
- Journals
- Journal of Clinical Oncology (12 papers)Annals of Oncology (12 papers)The Lancet (10 papers)Breast Cancer Research and Treatment (9 papers)The Breast (7 papers)
- Partner nations
- United KingdomUnited StatesBelgium
In The Last Decade
Ian Smith
254 papers receiving 21.7k citations
Ian Smith's Hit Papers
Peers
Comparison fields: 5 of 209
- Cancer Research 6.2k
- Oncology 9.7k
- Radiology, Nuclear Medicine and Imaging 2.9k
- Linguistics and Language 602
- Pulmonary and Respiratory Medicine 3.5k
Countries citing papers authored by Ian Smith
This map shows the geographic impact of Ian Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Smith more than expected).
Fields of papers citing papers by Ian Smith
This network shows the impact of papers produced by Ian Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Smith. The network helps show where Ian Smith may publish in the future.
Co-authors
The 25 scholars most cited alongside Ian Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 270 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Hit paper breakdown → | 2005 | 4136 |
| 2 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2950 |
| 3 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Hit paper breakdown → | 2007 | 1251 |
| 4 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 915 |
| 5 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 792 |
| 6 | A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Hit paper breakdown → | 2003 | 771 |
| 7 | Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 Hit paper breakdown → | 2007 | 746 |
| 8 | Dialects in contact. By Peter Trud Gill. (Language in society. 10.) Oxford: Blackwell. 1986. Pp. viii. 174. Hit paper breakdown → | 1987 | 664 |
| 9 | Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Hit paper breakdown → | 2011 | 521 |
| 10 | Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation Hit paper breakdown → | 2017 | 454 |
| 11 | 2013 | 400 | |
| 12 | 2014 | 389 | |
| 13 | 2011 | 310 | |
| 14 | 2002 | 308 | |
| 15 | 2015 | 305 | |
| 16 | 2014 | 275 | |
| 17 | 2011 | 267 | |
| 18 | Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial Hit paper breakdown → | 2019 | 264 |
| 19 | 2007 | 258 | |
| 20 | 2010 | 238 |
About Ian Smith
Ian Smith is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Gender Studies and Genetics, having authored 270 papers that have together received 22.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (37 papers), HER2/EGFR in Cancer Research (35 papers), Estrogen and related hormone effects (18 papers), Pulsed Power Technology Applications (16 papers), Cancer Treatment and Pharmacology (16 papers), Obstructive Sleep Apnea Research (15 papers), Gyrotron and Vacuum Electronics Research (13 papers) and Gender, Labor, and Family Dynamics (10 papers). The work is most often cited by research in Cancer Research (6.2k citations), Oncology (9.7k citations), Radiology, Nuclear Medicine and Imaging (2.9k citations), Linguistics and Language (602 citations) and Pulmonary and Respiratory Medicine (3.5k citations). Ian Smith has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Mitch Dowsett, Toby J Lasserson, Aron Goldhirsch, Richard D. Gelber, Dariusz Woźniak, Felix FitzRoy, Alan Stuart Coates, Beat J. K. Thurlimann, Andrew Craig Schofield and Andrew W. Hutcheon. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Lancet, Breast Cancer Research and Treatment and The Breast.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.